联合检测血清肿瘤标志物在肺癌诊断中的价值

The Value of Combined Detection of Serum Tumor Makers in the Diagnosis of Lung Cancer

目的探讨4种肿瘤标志物联合检测在肺癌诊断中的意义。方法将2012年2月至2014年7月我院收治的肺癌患者90例作为实验组,同期收治的肺部良性病变患者80例,作为肺良性病变组.对其SCC、CEA、CYFRA21、NSE水平进行检测,并对其敏感度进行对比分析。结果肺癌患者组血清中SCC、CEA、CYFRA21、NSE水平与肺部良性病变组相比,显著升高(P<0.05)。与单项检查比较,联合检查4项标志物可提高诊断肺癌的敏感度。结论分别测定患者SCC、CEA、CYFRA21、NSE的水平,敏感性较低,用于诊断肺癌有一定的局限性,而联合检测上述4项肿瘤标志物可提高诊断的灵敏度,对诊断肺癌有重要的参考价值。

Objective To explore the value of joint detection of four kinds of tumor markers in the diagnosis of lung cancer. Methods 90 cases who had been diagnosis as lung cancer were selected as observation group. 80 cases with benign pulmonary disease were selected as benign groups. The serum SCC,CEA,CYFRA21-1 and NSE levels in all cases were detected. Results The serum levels of SCC,CEA,CYFRA21-1 and NSE in lung cancer group were significantly higher than that of benign lung disease group（P〈0. 05）. The positive rate of joint detection of four kinds of tumor markers was significantly higher than that of any single detection（P〈0. 05）. Conclusion The single detection of serum SCC,CEA,CYFRA21-1 and NSE levels in diagnosis of lung cancer has certain limitations with low sensitivity,and the combined detection could increase the sensitivity and has important reference value in the diagnosis lung cancer.